Abstract:
BACKGROUND:Tuberculosis, which is often undiagnosed, is the major cause of death among HIV-positive people. We aimed to test whether the use of a clinical algorithm enabling the initiation of empirical tuberculosis treatment by nurses in primary health-care clinics would reduce mortality compared with standard of care for adults with advanced HIV disease. METHODS:In this open-label cluster-randomised controlled trial, we recruited individuals from 24 primary health-care clinics in South Africa. The clinics were randomly assigned (1:1) to either deliver an intervention or routine care (control) using computer-generated random numbers. Eligible participants were HIV-positive adults (aged ≥18 years) with CD4 counts of 150 cells per μL or less, who had not had antiretroviral therapy (ART) in the past 6 months or tuberculosis treatment in the past 3 months, and did not require urgent hospital referral. In intervention clinics, study nurses assessed participants on the basis of tuberculosis symptoms, body-mass index, point-of-care haemoglobin concentrations, and urine lipoarabinomannan assay results. Participants classified by a study algorithm as having high probability of tuberculosis (positive urine lipoarabinomannan assay, body-mass index <18·5 kg/m2, or haemoglobin concentration <100 g/L) were recommended to start tuberculosis treatment immediately followed by ART 2 weeks later; participants classified as medium probability (tuberculosis symptoms, no high probability criteria) were recommended to have symptom-guided investigation; and participants classified as low probability (no tuberculosis symptoms or high probability criteria) were recommended to start ART immediately. In standard-of-care clinics, participants received treatment in accordance with South African guidelines. Investigators and participants were aware of treatment allocation. The primary outcome was all-cause mortality at 6 months, assessed in the intention-to-treat population. Safety was also analysed in the intention-to treat population. This trial is registered with the ISRCTN registry, ISRCTN35344604, and the South African National Clinical Trials Register, DOH-27-0812-3902. FINDINGS:Between Dec 19, 2012, and Dec 18, 2014, 3091 individuals were screened for eligibility, of whom 3053 were recruited, and 3022 (1507 participants in the intervention group and 1515 participants in the control group) were analysed for the primary outcome. 930 (61·7%) of 1507 participants in the intervention group versus 172 (11·4%) of 1515 participants in the control group had started tuberculosis treatment by 2 months. At 6 months, the mortality rate was 19·0 deaths per 100 person-years for the intervention group versus 21·6 deaths per 100 person-years in the control group (unadjusted hazard ratio [HR] 0·92, 95% CI 0·67-1·26, p=0·58; adjusted HR 0·87, 0·61-1·24, p=0·41). 28 (1·9%) of 1507 participants in the intervention group and ten (0·7%) of 1515 participants in the control group reported serious or severe adverse events. Grade 3 or 4 nausea and vomiting was the most common adverse event (ten participants in the intervention group and four participants in the control group). Among participants with adverse events, eight participants (six participants in the intervention group and two participants in the control group) died; none of the six deaths in the intervention group were attributed to the study intervention. INTERPRETATION:Our intervention substantially increased coverage of tuberculosis treatment in this high-risk population, but did not reduce mortality. FUNDING:Joint Global Health Trials (Medical Research Council, Department for International Development, Wellcome Trust).
journal_name
Lancet HIVjournal_title
The lancet. HIVauthors
Grant AD,Charalambous S,Tlali M,Karat AS,Dorman SE,Hoffmann CJ,Johnson S,Vassall A,Churchyard GJ,Fielding KLdoi
10.1016/S2352-3018(19)30266-8subject
Has Abstractpub_date
2020-01-01 00:00:00pages
e27-e37issue
1eissn
2405-4704issn
2352-3018pii
S2352-3018(19)30266-8journal_volume
7pub_type
杂志文章,随机对照试验相关文献
Lancet HIV文献大全abstract:BACKGROUND:The burden of HIV in transgender women (transwomen) in Brazil remains unknown. We aimed to estimate HIV prevalence among transwomen in Rio de Janeiro and to identify predictors of newly diagnosed HIV infections. METHODS:We recruited transwomen from Rio de Janeiro, Brazil, by respondent-driven sampling. Elig...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(17)30015-2
更新日期:2017-04-01 00:00:00
abstract:BACKGROUND:Novel strategies are needed to increase retention in and uptake of prevention of mother-to-child HIV transmission (PMTCT) services in sub-Saharan Africa. We aimed to determine whether small, increasing cash payments, which were conditional on attendance at scheduled clinic visits and receipt of proposed serv...
journal_title:The lancet. HIV
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3018(15)00247-7
更新日期:2016-02-01 00:00:00
abstract::Progress in the development and introduction of paediatric formulations for key infectious diseases is poor in low-income and middle-income countries (LMICs). Although major steps have been made in the scale-up of antiretroviral medicines in LMICs, the development and deployment of formulations for infants and childre...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(18)30005-5
更新日期:2018-05-01 00:00:00
abstract::In our work as clinicians, researchers, and immigrant rights advocates, we have noted increased anxiety about the possibility of deportation and disruptions in care among immigrants with HIV. Before the 2016 US elections, patients rarely asked about HIV treatment in their home countries. However, since the increase in...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(18)30074-2
更新日期:2018-10-01 00:00:00
abstract:BACKGROUND:Standard approaches to estimation of losses in the HIV cascade of care are typically cross-sectional and do not include the population stages before linkage to clinical care. We used indiviual-level longitudinal cascade data, transition by transition, including population stages, both to identify the health-...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(16)30224-7
更新日期:2017-05-01 00:00:00
abstract::South Africa intends to include dolutegravir in its first-line antiretroviral therapy (ART) regimen because of cost savings, the drug's high barrier to resistance, and efficacy. However, recent data from Botswana suggest potential teratogenicity of dolutegravir. WHO recommends that non-pregnant women of childbearing a...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(18)30249-2
更新日期:2018-12-01 00:00:00
abstract:BACKGROUND:Pilot studies suggest that ritonavir-boosted darunavir could show high efficacy at doses below those currently approved. We investigated whether switch to 400 mg of darunavir boosted with 100 mg ritonavir once daily could show equivalent efficacy to continuation of ritonavir-boosted lopinavir (a protease inh...
journal_title:The lancet. HIV
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3018(19)30081-5
更新日期:2019-07-01 00:00:00
abstract:BACKGROUND:Incarceration provides an opportunity for engagement in HIV care but is associated with poor HIV treatment outcomes after release. We aimed to assess post-release linkage to HIV care (LTC) and the effect of transitional case management services. METHODS:To create a retrospective cohort of all adults with HI...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(17)30209-6
更新日期:2018-02-01 00:00:00
abstract:BACKGROUND:The South African national HIV plan recommends pre-exposure prophylaxis (PrEP) for transgender women, whose HIV prevalence estimates are as high as 25% in sub-Saharan Africa. The aim of this study was to explore PrEP awareness, uptake, and willingness, as well as associated barriers and facilitators, in orde...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(20)30119-3
更新日期:2020-12-01 00:00:00
abstract:BACKGROUND:Whether or not the association between some antiretrovirals used in HIV infection and chronic kidney disease is cumulative is a controversial topic, especially in patients with initially normal renal function. In this study, we aimed to investigate the association between duration of exposure to antiretrovir...
journal_title:The lancet. HIV
pub_type: 临床试验,杂志文章
doi:10.1016/S2352-3018(15)00211-8
更新日期:2016-01-01 00:00:00
abstract:BACKGROUND:Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against the most common NNRTI-resistant HIV-1 variants. We compared doravirine with ritonavir-boosted darunavir, when both were given with two...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3018(18)30021-3
更新日期:2018-05-01 00:00:00
abstract:BACKGROUND:Switching from therapy based on a boosted protease inhibitor to bictegravir, emtricitabine, and tenofovir alafenamide could avoid drug interactions and unwanted side-effects in virologically suppressed adults with HIV-1 infection, while maintaining a high barrier to resistance and providing a simplified once...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3018(18)30091-2
更新日期:2018-07-01 00:00:00
abstract:BACKGROUND:Although antiretroviral regimens containing integrase inhibitors rapidly suppress HIV viral load in non-pregnant adults, few published data from randomised controlled trials have compared the safety and efficacy of any integrase inhibitor to efavirenz when initiated during pregnancy. We compared safety and e...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3018(20)30038-2
更新日期:2020-05-01 00:00:00
abstract:BACKGROUND:Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of switching to a single-tablet regimen of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boosted protease inhi...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3018(17)30179-0
更新日期:2018-01-01 00:00:00
abstract:BACKGROUND:ADVANCE compared the efficacy and safety of two antiretroviral first-line combinations (dolutegravir combined with emtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a third regimen (efavirenz combined with emtricitabine and tenofovir disoproxil fumarate) previously recomm...
journal_title:The lancet. HIV
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3018(20)30241-1
更新日期:2020-10-01 00:00:00
abstract:BACKGROUND:In patients with HIV, immune reconstitution after antiretroviral therapy (ART) is often incomplete. We assessed the probability of patients reaching a CD4/CD8 ratio of 1 or more after the start of ART and its association with the onset of non-AIDS-defining events and death. METHODS:We did an analysis of the...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(15)00006-5
更新日期:2015-03-01 00:00:00
abstract:BACKGROUND:Universal antiretroviral therapy (ART), as per the 2015 WHO recommendations, might reduce population HIV incidence. We investigated the effect of universal test and treat on HIV acquisition at population level in a high prevalence rural region of South Africa. METHODS:We did a phase 4, open-label, cluster r...
journal_title:The lancet. HIV
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3018(17)30205-9
更新日期:2018-03-01 00:00:00
abstract:BACKGROUND:The HIV epidemic in the USA is a collection of diverse local microepidemics. We aimed to identify optimal combination implementation strategies of evidence-based interventions to reach 90% reduction of incidence in 10 years, in six US cities that comprise 24·1% of people living with HIV in the USA. METHODS:...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(20)30033-3
更新日期:2020-07-01 00:00:00
abstract::The evaluation of immune-based approaches to achieve an antiretroviral therapy free remission of HIV infection requires proven efficacy through antiretroviral therapy interruption placebo-controlled trials. This approach is not without risk to participants and innovative trial designs need to be developed that minimis...
journal_title:The lancet. HIV
pub_type: 杂志文章,评审
doi:10.1016/S2352-3018(19)30082-7
更新日期:2019-05-01 00:00:00
abstract:BACKGROUND:As access to antiretroviral therapy (ART) expands, increasing numbers of older patients will start treatment and need specialised long-term care. However, the effect of age in ART programmes in resource-constrained settings is poorly understood. The HIV epidemic is ageing rapidly and South Africa has one of ...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究
doi:10.1016/S2352-3018(15)00113-7
更新日期:2015-09-01 00:00:00
abstract:BACKGROUND:Immune Reconstitution Inflammatory Syndrome (IRIS) is a common complication of antiretroviral therapy (ART) in HIV-infected patients. IRIS is associated with an increased risk of hospitalization and death. We ascertained whether CCR5 blockade using maraviroc reduces the risk of IRIS. METHODS:The CADIRIS stu...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(14)70027-X
更新日期:2014-11-01 00:00:00
abstract:BACKGROUND:The HIV epidemic in the population of Nairobi as a whole is in decline, but a concentrated sub-epidemic persists in key populations. We aimed to identify an optimal portfolio of interventions to reduce HIV incidence for a given budget and to identify the circumstances in which pre-exposure prophylaxis (PrEP)...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(17)30021-8
更新日期:2017-05-01 00:00:00
abstract:BACKGROUND:Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with potent antiviral activity and a long half-life when administered by injection that prevented simian-HIV infection upon repeat intrarectal challenge in male macaques. We aimed to assess the safety, tolerability, and pharmacokinetic...
journal_title:The lancet. HIV
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/S2352-3018(17)30068-1
更新日期:2017-08-01 00:00:00
abstract:BACKGROUND:As HIV incidence and mortality continue to increase in eastern Europe and central Asia, particularly among people who inject drugs (PWID), it is crucial to effectively scale-up opioid agonist therapy (OAT), such as methadone or buprenorphine maintenance therapy, to optimise HIV outcomes. With low OAT coverag...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(19)30373-X
更新日期:2020-02-01 00:00:00
abstract:BACKGROUND:HIV evolves rapidly and therefore infections with similar genetic sequences are likely linked by recent transmission events. Clusters of related infections can represent subpopulations with high rates of transmission. We describe the implementation of an automated near real-time system to monitor and charact...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(16)00046-1
更新日期:2016-05-01 00:00:00
abstract:BACKGROUND:In high HIV burden settings, maximising the coverage of prevention strategies is crucial to achieving epidemic control. However, little is known about the reach and effect of these strategies in some communities. METHODS:We did a cross-sectional community survey in the adjacent Greater Edendale and Vulindle...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(18)30104-8
更新日期:2018-08-01 00:00:00
abstract:BACKGROUND:Isoniazid preventive therapy prevents active tuberculosis in people with HIV, but previous studies have found no evidence of benefit in people with HIV who had a negative tuberculin skin test, and a non-significant effect on mortality. We aimed to estimate the effect of isoniazid preventive therapy given wit...
journal_title:The lancet. HIV
pub_type: 杂志文章,meta分析
doi:10.1016/S2352-3018(20)30299-X
更新日期:2021-01-01 00:00:00
abstract:BACKGROUND:Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These vaccine components were adapted to express HIV-1 antigens from strains circulating in South Africa, and the adjuvant was changed to increase im...
journal_title:The lancet. HIV
pub_type: 杂志文章,随机对照试验
doi:10.1016/S2352-3018(18)30071-7
更新日期:2018-07-01 00:00:00
abstract:BACKGROUND:The number of people on antiretroviral therapy (ART) requiring treatment monitoring in low-resource settings is rapidly increasing. Point-of-care (POC) testing for ART monitoring might alleviate burden on centralised laboratories and improve clinical outcomes, but its cost-effectiveness is unknown. METHODS:...
journal_title:The lancet. HIV
pub_type: 杂志文章
doi:10.1016/S2352-3018(20)30279-4
更新日期:2020-12-18 00:00:00
abstract:BACKGROUND:Although lifelong combination antiretroviral therapy (ART) is recommended for all individuals with HIV, few data exist for pregnancy outcomes associated with ART initiation before conception. We assessed adverse pregnancy outcomes associated with ART initiated before conception compared with that of ART star...
journal_title:The lancet. HIV
pub_type: 杂志文章,meta分析,评审
doi:10.1016/S2352-3018(16)30195-3
更新日期:2017-01-01 00:00:00